Gotham Asset Management LLC Takes $295,000 Position in NeoGenomics, Inc. (NASDAQ:NEO)

Gotham Asset Management LLC acquired a new stake in NeoGenomics, Inc. (NASDAQ:NEO) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 23,378 shares of the medical research company’s stock, valued at approximately $295,000.

Several other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. raised its holdings in shares of NeoGenomics by 8.7% in the 4th quarter. BlackRock Inc. now owns 5,519,647 shares of the medical research company’s stock valued at $69,603,000 after purchasing an additional 440,621 shares in the last quarter. Vanguard Group Inc. grew its position in NeoGenomics by 24.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,839,641 shares of the medical research company’s stock worth $58,939,000 after purchasing an additional 743,245 shares during the last quarter. Vanguard Group Inc grew its position in NeoGenomics by 24.0% during the 3rd quarter. Vanguard Group Inc now owns 3,839,641 shares of the medical research company’s stock worth $58,939,000 after purchasing an additional 743,245 shares during the last quarter. Brown Advisory Inc. grew its position in NeoGenomics by 66.2% during the 4th quarter. Brown Advisory Inc. now owns 2,441,468 shares of the medical research company’s stock worth $30,787,000 after purchasing an additional 972,288 shares during the last quarter. Finally, Eagle Asset Management Inc. grew its position in NeoGenomics by 5.4% during the 4th quarter. Eagle Asset Management Inc. now owns 2,274,143 shares of the medical research company’s stock worth $28,676,000 after purchasing an additional 116,717 shares during the last quarter. 76.89% of the stock is owned by institutional investors and hedge funds.

NEO stock traded up $0.21 during trading on Friday, reaching $20.47. 530,382 shares of the company were exchanged, compared to its average volume of 1,180,160. The company has a market cap of $1.93 billion, a P/E ratio of 157.46 and a beta of 0.93. NeoGenomics, Inc. has a 52-week low of $9.49 and a 52-week high of $22.17. The company has a current ratio of 1.70, a quick ratio of 1.56 and a debt-to-equity ratio of 0.31.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, February 19th. The medical research company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. The firm had revenue of $76.50 million for the quarter, compared to the consensus estimate of $71.29 million. NeoGenomics had a net margin of 0.95% and a return on equity of 2.25%. The firm’s revenue was up 24.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.05 earnings per share. On average, equities research analysts expect that NeoGenomics, Inc. will post 0.18 earnings per share for the current year.

Several brokerages have issued reports on NEO. BidaskClub downgraded shares of NeoGenomics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 18th. Needham & Company LLC lifted their target price on shares of NeoGenomics from $19.00 to $22.00 and gave the company a “buy” rating in a report on Friday, March 29th. CIBC raised shares of NeoGenomics from a “neutral” rating to an “outperform” rating and lowered their target price for the company from $18.00 to $15.00 in a report on Tuesday, March 12th. Zacks Investment Research downgraded shares of NeoGenomics from a “buy” rating to a “hold” rating in a report on Saturday, March 2nd. Finally, ValuEngine raised shares of NeoGenomics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 10th. One investment analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $19.55.

In other NeoGenomics news, VP Jennifer Balliet sold 30,000 shares of NeoGenomics stock in a transaction dated Thursday, February 28th. The shares were sold at an average price of $19.57, for a total transaction of $587,100.00. Following the completion of the transaction, the vice president now owns 40,000 shares in the company, valued at $782,800. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Robert J. Shovlin sold 186,014 shares of NeoGenomics stock in a transaction dated Wednesday, February 27th. The stock was sold at an average price of $18.96, for a total transaction of $3,526,825.44. Following the transaction, the insider now owns 40,166 shares of the company’s stock, valued at approximately $761,547.36. The disclosure for this sale can be found here. In the last three months, insiders have sold 263,524 shares of company stock worth $5,019,496. 12.20% of the stock is owned by insiders.

TRADEMARK VIOLATION NOTICE: “Gotham Asset Management LLC Takes $295,000 Position in NeoGenomics, Inc. (NASDAQ:NEO)” was reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.baseballdailydigest.com/news/2019/04/26/gotham-asset-management-llc-takes-position-in-neogenomics-inc-neo.html.

NeoGenomics Company Profile

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

Read More: What is a Call Option?

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.